A panelist discusses how tumor heterogeneity (both spatial and temporal) affects molecular testing reliability in ovarian cancer, highlighting that although most biomarkers show little heterogeneity, ...
(a) Schematic of IHoM and IHeM models. NC: neutral cells; AC: cells carrying antigen mutations; IC: immune-recognizable cells; EC: immune-escaped cells. (b) Response of IHoM and IHeM to monotherapies ...
What innovative approaches in imaging are you seeing advancing immuno-oncology? Two innovations stand out, and they are not mutually exclusive. Molecular imaging, such as PET, utilizes specific ...
Australian scientists have discovered that DNA barcoding can be used to track cancer cells in solid and liquid biopsies, empowering future research into more reliable breast cancer diagnosis and ...
In recognition of Breast Cancer Awareness Month, join us for a live webinar to uncover the complexity of tumor biology and the surprising resilience of normal tissue. This event will feature two ...
Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.
Mutation profiling of appendiceal cancer: Distinguishing tumor grades, comprehensive mutation landscape, and ctDNA as a discovery tool. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Efficacy and safety of regorafenib combined with immune checkpoint inhibitors in advanced hepatocellular carcinoma patients progressing after lenvatinib treatment. This is an ASCO Meeting Abstract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results